Glatiramer is an immunomodulator, used to treat multiple sclerosis. The risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with Anthrax immune globulin human ...

Glatiramer acetate is an approved drug for relapsing-remitting multiple sclerosis. An article published online first and in an upcoming edition of the Lancet shows that early treatment with this ...

Glatiramer acetate and INF-beta products provided a long-term treatment option for some patients, as a subset of patients continued with treatment for more than 10 years.

October 26, 2007 (Prague, Czech Republic) — Results of a head-to-head clinical trial of glatiramer acetate ( Copaxone, Teva Pharmaceutical Industries) and interferon beta-1a ( Rebif , Merck ...

BG-12 (dimethyl fumarate) is in development as an oral treatment for relapsing–remitting multiple sclerosis, which is commonly treated with parenteral agents (interferon or glatiramer acetate ...

Mylan introduced 20 mg and 40 mg generic versions of glatiramer acetate in October 2017, near the end date of the study. By the fourth quarter of 2017, more than 26% of total DMT utilization was a ...

The authorities’ approval formally acknowledges that Synthon’s glatiramer acetate is regarded therapeutically equivalent to the reference product based on the Quality, Non-Clinical ...

Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application for glatiramer acetate (GA) Depot 40mg for the treatment of relapsing forms of multiple sclerosis (RMS).

Glatiramer Acetate Injection had annual sales of US$ 719mn in the United States (IQVIA MAT Mar-2025). The group now has 426 approvals and has so far filed 492* ANDAs since the commencement of the ...

Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.